Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Weekly rifapentine and isoniazid (3HP) is gaining popularity for latent tuberculosis infection treatment because of its short course and high completion rate. Prior to widespread use, comprehensive 3HP treatment assessment covering an all-age population is essential.
METHODS: Participants receiving ≥1 3HP dose from September 2014 to December 2019 were stratified into elderly (≥65 years), middle-aged (>35 & <65 years), and younger (≤35 years) age groups. This study investigated the impact of age on treatment outcome, particularly systemic drug reactions (SDRs) and 3HP discontinuation.
RESULTS: Overall, 134 of 579 (23.1%) participants were elderly. The completion rate was 83.1% overall and was highest and lowest in the younger group (94.5%) and elderly (73.9%) group, respectively. However, the 3HP discontinuation rate was not significantly different among the 3 groups in multivariate logistic regression analysis. In total, 362 (62.5%) participants experienced 1 or more adverse drug reactions (ADRs), of which 38 (10.5%) and 98 (27.1%) required temporary and permanent treatment interruption, respectively. The SDR risk was 11.2% in overall and 17.1% in the middle-aged group, 3.04-fold higher than that in the elderly group (P = .025). This finding was consistently observed in different clinical settings. Hypertensive events accompanied with flu-like symptoms occurred in 11.2% of elderly participants, and accounted for 50% of grade ≥3 ADRs.
CONCLUSIONS: With proper medical support and programmatic follow-up, the 3HP completion rate is >70% even in elderly participants. In middle-aged and elderly individuals, 3HP should be employed with caution because of risk of SDRs and hypertensive events, respectively. Summary: Under programmatic medical support, widespread use of weekly rifapentine and isoniazid (3HP) for latent tuberculosis treatment is possible for its high completion rate. 3HP should be employed with caution for risk of systemic drug reactions and hypertensive events in middle-aged and elderly individuals, respectively.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 5 vom: 07. Sept., Seite e1064-e1071 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Hung-Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.09.2021 Date Revised 22.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1741 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317822748 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317822748 | ||
| 003 | DE-627 | ||
| 005 | 20231225164053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1741 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1059.xml |
| 035 | |a (DE-627)NLM317822748 | ||
| 035 | |a (NLM)33215187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Hung-Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2021 | ||
| 500 | |a Date Revised 22.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Weekly rifapentine and isoniazid (3HP) is gaining popularity for latent tuberculosis infection treatment because of its short course and high completion rate. Prior to widespread use, comprehensive 3HP treatment assessment covering an all-age population is essential | ||
| 520 | |a METHODS: Participants receiving ≥1 3HP dose from September 2014 to December 2019 were stratified into elderly (≥65 years), middle-aged (>35 & <65 years), and younger (≤35 years) age groups. This study investigated the impact of age on treatment outcome, particularly systemic drug reactions (SDRs) and 3HP discontinuation | ||
| 520 | |a RESULTS: Overall, 134 of 579 (23.1%) participants were elderly. The completion rate was 83.1% overall and was highest and lowest in the younger group (94.5%) and elderly (73.9%) group, respectively. However, the 3HP discontinuation rate was not significantly different among the 3 groups in multivariate logistic regression analysis. In total, 362 (62.5%) participants experienced 1 or more adverse drug reactions (ADRs), of which 38 (10.5%) and 98 (27.1%) required temporary and permanent treatment interruption, respectively. The SDR risk was 11.2% in overall and 17.1% in the middle-aged group, 3.04-fold higher than that in the elderly group (P = .025). This finding was consistently observed in different clinical settings. Hypertensive events accompanied with flu-like symptoms occurred in 11.2% of elderly participants, and accounted for 50% of grade ≥3 ADRs | ||
| 520 | |a CONCLUSIONS: With proper medical support and programmatic follow-up, the 3HP completion rate is >70% even in elderly participants. In middle-aged and elderly individuals, 3HP should be employed with caution because of risk of SDRs and hypertensive events, respectively. Summary: Under programmatic medical support, widespread use of weekly rifapentine and isoniazid (3HP) for latent tuberculosis treatment is possible for its high completion rate. 3HP should be employed with caution for risk of systemic drug reactions and hypertensive events in middle-aged and elderly individuals, respectively | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a age | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a latent tuberculosis infection | |
| 650 | 4 | |a rifapentine | |
| 650 | 4 | |a systemic drug reaction | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Isoniazid |2 NLM | |
| 650 | 7 | |a V83O1VOZ8L |2 NLM | |
| 650 | 7 | |a Rifampin |2 NLM | |
| 650 | 7 | |a VJT6J7R4TR |2 NLM | |
| 650 | 7 | |a rifapentine |2 NLM | |
| 650 | 7 | |a XJM390A33U |2 NLM | |
| 700 | 1 | |a Lee, Meng-Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Meng-Hsuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Po-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chun-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Sheu, Chau-Chyun |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Ping-Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tun-Chieh |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jann-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Inn-Wen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 5 vom: 07. Sept., Seite e1064-e1071 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:5 |g day:07 |g month:09 |g pages:e1064-e1071 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1741 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 5 |b 07 |c 09 |h e1064-e1071 | ||